Myriad Genetics, Inc.
MYGN
$3.82
-$0.09-2.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -4.48% | 1.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.48% | 1.99% | |||
| Cost of Revenue | -0.32% | 1.78% | |||
| Gross Profit | -6.27% | 2.09% | |||
| SG&A Expenses | 9.25% | -10.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.06% | -7.07% | |||
| Operating Income | -743.33% | 87.12% | |||
| Income Before Tax | -283.15% | 66.03% | |||
| Income Tax Expenses | -- | -183.33% | |||
| Earnings from Continuing Operations | -331.65% | 71.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -331.65% | 71.17% | |||
| EBIT | -743.33% | 87.12% | |||
| EBITDA | -233.33% | 189.72% | |||
| EPS Basic | -329.63% | 71.22% | |||
| Normalized Basic EPS | -361.20% | 76.41% | |||
| EPS Diluted | -329.63% | 71.22% | |||
| Normalized Diluted EPS | -361.20% | 76.41% | |||
| Average Basic Shares Outstanding | 0.43% | 0.21% | |||
| Average Diluted Shares Outstanding | 0.43% | 0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||